Paper Details

  1. Home
  2. Paper Details

Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.

Author: DotyErin, KomoriMika, KregeJohn H, MagisDelphine, RathmannSuchitrita S, TepperStewart J, VargasBert B, VasudevaRaghavendra

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study aims to identify factors that predict how well patients respond to lasmiditan, a medication for migraine headaches. The study will look at different patient characteristics, migraine history, and individual migraine attacks to understand who is most likely to benefit from this medication. The researchers will also focus on groups of patients who have traditionally had difficulty responding to certain migraine treatments.
Paper Details　
Original Abstract of the Article :
To identify factors predicting response (2-hour headache pain freedom or most bothersome symptom freedom) to lasmiditan based on individual patient characteristics, migraine disease characteristics, and migraine attack characteristics. Further, efficacy specifically in difficult-to-treat patient/mig...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496706/

データ提供：米国国立医学図書館（NLM）

Evaluating the Efficacy of Lasmiditan for Acute Migraine Attacks

The relentless pain of migraine attacks can be a debilitating experience. This research investigates the efficacy of lasmiditan, a novel medication for the acute treatment of migraine attacks, in a group of patients with difficult-to-treat migraines.

A New Hope for Difficult-to-Treat Migraines

The study aimed to identify factors that predict response to lasmiditan, analyzing patient characteristics, migraine disease characteristics, and attack characteristics. The results provide valuable insights into the potential of lasmiditan in effectively managing acute migraine attacks, even in patients who have not responded well to traditional therapies.

Exploring New Avenues for Migraine Treatment

This research sheds light on a potential new avenue for treating acute migraine attacks, particularly for those who have not found relief from traditional therapies. It's a reminder that the desert of migraine research is vast and evolving, and innovative approaches are constantly emerging.

Dr.Camel's Conclusion

This study offers promising insights into the potential of lasmiditan in effectively managing acute migraine attacks, even in those who have not responded well to traditional therapies. It's a testament to the ongoing quest for better and more effective treatments in the vast and complex desert of migraine research. As a fellow traveler on this journey, I am encouraged by these promising findings and hope that further research will continue to illuminate the full potential of lasmiditan in alleviating the debilitating pain of migraine attacks.

Date :
  1. Date Completed 2021-11-08
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

32634275

DOI: Digital Object Identifier

PMC7496706

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.